CD274 and skin squamous cell carcinoma: Taken together, cemiplimab offers notable efficacy and convenient administration in advanced cSCC, with PD-L1 expression serving as a predictive biomarker of response, whereas pembrolizumab requires individualized dosing to optimize therapeutic outcomes.